CN Patent

CN113038953B — 用于治疗癌症的包括krasg12c抑制剂和一种或多种其他药学活性药剂的组合疗法

Assigned to Amgen Inc · Expires 2024-08-23 · 2y expired

What this patent protects

本发明提供了包括KRAS G12C 抑制剂(例如(参见下式))或其药学上可接受的盐和一种或多种其他药学活性药剂的组合疗法，特别是用于治疗癌症。本发明还涉及用于治疗癌症的含有KRAS G12C 抑制剂和一种或多种其他药学活性药剂的药物组合物。

USPTO Abstract

本发明提供了包括KRAS G12C 抑制剂(例如(参见下式))或其药学上可接受的盐和一种或多种其他药学活性药剂的组合疗法，特别是用于治疗癌症。本发明还涉及用于治疗癌症的含有KRAS G12C 抑制剂和一种或多种其他药学活性药剂的药物组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN113038953B
Jurisdiction
CN
Classification
—
Expires
2024-08-23
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.